Emerging Antibody Engineering Strategies and Applications for Immunotherapy of Cancer

In the past decade, cancer immunotherapy has revolutionized the treatment of hematological and solid tumors, resulting in the approval of checkpoint inhibitory antibodies, CAR-T cell therapies, and T cells engaging bispecific antibodies. Despite this progress, the lack of response and/or relapse and subsequent resistance to immunotherapy remain major clinical challenges requiring the development of optimized therapeutic agents and novel principles for targeting cancer. For this purpose, the application of state-of-the-art antibody engineering continues to play a key role. This Special Issue covers recent progress and novel concepts in the engineering of antibody-based immunotherapies, including monoclonal antibodies, antibody engineering, bi- and multispecific antibodies, photo-and radioimmunotherapy and CAR-T cell therapy manufacturing.